Nisoldipine CC: Clinical experience in hypertension

Cardiology (Switzerland)

Volumn 88, Issue , 1997, Pages 56-62

  Langana, J ^a   Rodriguez Manasb L ^b   Sarelic, P ^c   Heiniga R ^d  

^a Baillieston Health Centre   (United Kingdom)

^b HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d BAYER AG   (Germany)

Author keywords

Ambulatory blood pressure monitoring; Hypertension; Nisoldipine

Indexed keywords

AMLODIPINE; ATENOLOL; ENALAPRIL; HYDROCHLOROTHIAZIDE; LISINOPRIL; NISOLDIPINE;

AMBULATORY MONITORING; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED RELEASE FORMULATION; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG TOLERABILITY; DRUG USE; EDEMA; FATIGUE; FOOD DRUG INTERACTION; HEADACHE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEART PALPITATION; HUMAN; HYPERTENSION; META ANALYSIS; NECK PAIN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBARACHNOID HEMORRHAGE; VISUAL IMPAIRMENT;

BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; DELAYED-ACTION PREPARATIONS; HUMANS; HYPERTENSION; NISOLDIPINE; RANDOMIZED CONTROLLED TRIALS; VENTRICULAR FUNCTION, LEFT;

EID: 0031012088     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000177466     Document Type: Article

References (25)

1. AHA: Heart and Stroke Facts 1995. Statistical Supplement. Dallas. The Association. 1994.
2. McMahon S. Pcto R. Cutler J. Collins R. Sorlie P. Neaton J. Abbot R. Godwin J. Dyer A. Stamlcr J: Blood pressure, stroke, and coronary' heart disease. 1. Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet 1990:335:765-774.
3. Collins R. Peto R, MacMahon S, Hebert P. Fic-bach NH. Ebcriein KA. Godwin J. Qizilbash N. Taylor JO. HcnnekensCH: Blood pressure, stroke and coronary heart disease. 2. Shortterm reductions in blood pressure: Overview of randomized drug trials in their epidemiological context. Lancet 1990:335:827-838.
4. Godfraind T. Salomonc S, Dessy C. Vehclst B. Dion R. Schocvacrts JC: Selectivity scale of calcium antagonists in the human cardiovascular system based on in vitro studies. J Cardiovasc Pharmacol 1992;20(suppl 5):S34-S41.
5. Daniels AD. Opie LH: Monotherapy with the calcium channel antagonist nisoldipinc for systemic hypertension and comparison with diuretic drugs. Am J Cardiol 1987:60:703-707.
6. Roscndorff C. Goodman C: Double-blind double-dummy crossover study of the efficacy and safety of nisoldipinc (BAYk5522) versus nifedipine. Curr Ther Res Clin Exp 1985:37:912- 920.
7. Fujii Y. Hatton S. Nagami K. Miyamoto M. Kamiya T. Nakahara K. Yokoyama T: The hypotensive effect of nisoldipine:24-hour blood pressure profile and serial alterations of renal and hormonal function. Curr Ther Res 1994:55:93-101.
8. Nakanishi T. Takahashi H. Yoshimura W. Hi-rabayashi M: Effects of nisoldipine on ambulatory blood pressure in patients with essential hypertension. Curr Ther Res Clin Exp 1991:50: 417-424.
9. Brigden G. Heber M. Caruana M. Lahiri A. Raftery EB: Once daily nisoldipine in hypertension: Cuff and ambulatory intra-arterial blood pressure. Eur J Clin Pharmacol 1989:37: 551-554.
10. Omvik P. Lund-Johansen P. Haugland H: Nisoldipinc central haemodynamics at rest and during exercise in essential hypertension: Acuteand chronic studies. J Hypcrtcns 1988:6: 95-103.
11. Lund-Johansen P. Omvik P: Central hemodynamic changes of calcium channel antagonists at rest and during exercise in essential hypertension. J Cardiovasc Pharmacol 1987: 10(suppl 1):S139-S148.
12. Eliahou HE. Herzog D. Battler A. Herz I. Cohen D: Nisoldipine decreases total peripheral resistance (TPR) and blood pressure (BP) in essential hypertension (abstract 233). Cardiovase Drugs Ther 1987:1.
13. Barjon JN, Rouleau JN, Bichel D, Juneau C, De Champlain J: Chronic renal and ncurohor-monal efTecIs of the calcium entry blocker ni-soldipine in patients with congestive heart failure. J Am Coll Cardiol 1987:9:622-630.
14. Zannad F: Clinical pharmacology of nisoldi-pine coat core. Am J Cardiol 1995;75:41E-45E.
15. Chandler MHH, Clifton GD. Lettieri JD. Maz-zu AL, Allinton DR. Thicncman AC. Foster TS. Harrison MR: Multiple dose pharmacokinetics of four different doses of nisoldipine in hypertensive patients. J Clin Pharmacol 1992; 32:571-575.
16. Opic LH. Muller FO. Myburgh DP. Rosen-dorff C. Sareli P, Seedat YK. Weich DJV. Luus HG: Efficacy and tolerability of nisoldipine CC in the treatment of essential hypertension. Am J Hypertens, in press.
17. Ruddy TD, Fodor JG. Sami MH: The efficacy and tolerability of oncc-daily nisoldipine coat-core versus lisinopril in the treatment of mild to moderate hypertension. Hypertension, submitted.
18. Millar-Craig MW, Bishop CN, Raftery EB: Circadian variation of blood pressure. Lancet 1978;i:795-797.
19. Kiowski W, Osswald S: Circadian variation of ischemic cardiac events. J Cardiovasc Pharmacol 1993:2 (suppl 2):S45-S48.
20. Agnoli A. Manfrcdi M. Mossuto L. Piccinelli A: Relationship between circadian rhythms and blood pressure and the pathogenesis of cerebrovascular insufficiency. Rev Neurol (Paris) 1975:131:597-606.
21. Tunstall Pedoc H, Clayton D. Morris JN. Brigdcn W, McDonald L: Coronary heart-attacks in East London. Lancet 1975;i:833-838.
22. Lasscter KC. Muller FO. Garrett BN. Marazzi P. Fedor JG: Pharmacokinetics, pharmacodynamics and clinical utility of nisoldipine coat core in the treatment of essential hypertension. Cardiovasc Rev Rep 1996:17:28-46.
23. Fodor JG: Comparative efficacy and tolerability of nisoldipine CC and hydrochlorothiazide in mild to moderate hypertension. Can J Cardiol. in press.
24. Marazzi P: A study to demonstrate the equivalence in efficacy and safety of once daily nisoldipine CC and amlodipine in the treatment of mild to moderate hypertension. Acta Ther 1996;22:23-36.
25. Schaefer HG, Hcinig R, Ahr G, Adelmann H. Tctzloff W. Kuhlmann J: Pharmacokinetic-pharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-rclease dosage form. Eur J Clin Pharm, in press.